Intellikine, Inc. Initiates Phase I Study of Targeted Cancer Therapeutic INK1117

Published: Oct 12, 2011

LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies. INK1117, a selective, orally available, small molecule inhibitor of the PI3Kalpha isoform has demonstrated impressive efficacy in several PI3Kalpha mutant-specific preclinical tumor models.

Back to news